Marketing authorisations under exceptional circumstances for oncology drugs: an analysis of approval and reimbursement decisions of four drugs

Van der Vossen AC, Nachtnebel A, Wild C

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
This report aims to provide insight into the authorisation under exceptional circumstances of oncology drugs.

Authors' conclusions
To successfully develop drugs for very rare conditions, it is important that industry, EMA and reimbursement agencies intensify the collaboration. On introduction these drugs cannot always prove their cost-effectiveness, therefore conditional coverage with evidence development, preferably on an international level, should be encouraged and facilitated.

Final publication URL
http://eprints.hta.lbg.ac.at/992/1/HTA-Projektbericht_ Nr.65.pdf

Indexing Status
Subject indexing assigned by CRD

MeSH
Drug Approval; Antineoplastic Agents; Compassionate Use Trials

Language Published
English

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: anna.nachtnebel@hta.lbg.ac.at

AccessionNumber
32013000255

Date abstract record published
22/04/2013